2008: Epidemiology and Health Services Research: Rheumatoid Arthritis
Search or Browse by Day

Epidemiology and Health Services Research: Rheumatoid Arthritis

Monday, October 27, 2008
773
The Rising Incidence of Rheumatoid Arthritis
774
Evaluating the Role of MRI in Early Rheumatoid Arthritis Diagnosis
775
Evaluating the Prognostic Role of MRI in Early Rheumatoid Arthritis
776
More Rheumatoid Arthritis or More Spondyloarthritis? Preliminary Results from the SPARK Survey of US and European Clinical Practice
777
Risk Of Onset Of Both Rheumatoid Arthritis And Other Chronic Arthritides During The First Year After Delivery
778
Mortality and Cancer Incidence in Korean Patients with Rheumatoid Arthritis
779
Differential Effect of Body Mass Index on Disease Activity in Rheumatoid Arthritis (RA) by Gender: Results from the QUEST-RA Study
780
Hydroxychloroquine Use Reduces Risk Of Diabetes In Rheumatoid Arthritis Patients
781
Assessment of Patient-Reported Outcomes from a Double-Blind Trial of Etanercept and Methotrexate Combination in Early Active Rheumatoid Arthritis: The COMET Trial
782
Scores of Rheumatoid Arthritis (RA) Disease Activity Indices can be Mapped to ACR responses, and Vice Versa
783
Understanding Why RA Treatment Preferences Differ by Race
784
Routine Assessment of Patient Index Data (RAPID3) Accurately Measures Disease Activity and Physical Functioning in Patients With Early Rheumatoid Arthritis (RA) Treated With Adalimumab (HUMIRA®)
785
Routine Assessment of Patient Index Data (RAPID3), a Patient-Based Measure of Disease Activity, Is Associated With Work Outcomes Among Patients With Early Rheumatoid Arthritis Taking Adalimumab (HUMIRA®)
786
Workplace Impacts of Adalimumab (HUMIRA®) in Patients With Rheumatoid Arthritis (RA)
787
Increasing intensity of treatment and decreasing work disability 2001 to 2007 in patients with rheumatoid arthritis in Germany
788
Adherence To Methotrexate In Patients With Rheumatoid Arthritis. A 10-year Pharmacoepidemiological Study
789
Physician - Patient Collaboration: Rheumatoid Arthritis Drug Regimen Decision Patterns
790
Declines in Rheumatoid Arthritis and Rheumatoid Vasculitis among US Veterans
791
Genetic Testing for Rituximab Responsiveness
792
Factors Affecting Referral and Treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs) for Patients with Rheumatoid Arthritis: Qualitative Interviews with Primary Care Physicians
793
Adalimumab (HUMIRA®) Plus MTX Combination Therapy Decreases Resource Use by Patients With Early Rheumatoid Arthritis
794
The Economic Consequences of Rheumatoid Arthritis: A Replication of the Medical Expenditure Panel Survey (MEPS) with Updated 2005 Data
795
Economic Benefit Of Achieving Clinical And Radiographic Remission With Etanercept As First Line Treatment In Severe And Highly Active Rheumatoid Arthritis Patients
796
Impact of Anti-TNF Therapies on Work Disability in Rheumatic Diseases
797
Cost-Effectiveness Simulation Model of Abatacept versus anti-TNF treatment strategies in Rheumatoid Arthritis in France
798
Working status in the BSR Biologics Register (BSRBR)
799
Healthcare Costs for Rheumatoid Arthritis Patients Treated with Abatacept, Infliximab, or Rituximab
800
The Impact of Rheumatoid Arthritis on Employment, Function and Productivity in the United States
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>